(NASDAQ: KROS) Keros Therapeutics's forecast annual revenue growth rate of 112.37% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 65.42%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.4%.
Keros Therapeutics's revenue in 2025 is $3,550,000.On average, 5 Wall Street analysts forecast KROS's revenue for 2025 to be $4,083,786,892, with the lowest KROS revenue forecast at $16,224,819, and the highest KROS revenue forecast at $9,329,270,810. On average, 3 Wall Street analysts forecast KROS's revenue for 2026 to be $1,257,423,457, with the lowest KROS revenue forecast at $527,306,611, and the highest KROS revenue forecast at $1,622,481,880.
In 2027, KROS is forecast to generate $1,379,109,598 in revenue, with the lowest revenue forecast at $608,430,705 and the highest revenue forecast at $2,028,102,350.